BINHUI BIOTECH
Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent Innovation Demonstration Zone. The company is committed to providing innovative products and services for the field of oncology integration (including diagnosis and treatment), and developing products and services that have independent intellectual property rights and can compete with other manufacturers on the international stage.
BINHUI BIOTECH
Industry:
Biotechnology
Founded:
2010-01-01
Address:
Wuhan, Hubei, China
Country:
China
Website Url:
http://www.binhui-bio.com.cn
Total Employee:
1+
Status:
Active
Contact:
027-87326962
Email Addresses:
[email protected]
Total Funding:
156.02 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network Apache Euro Apple Mobile Web App Capable DigiCert SSL Apple Mobile Web App Status Bar Style Japanese Yen Encryption Everywhere
Similar Organizations
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Immunicom
Immunicom is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Neomorph
Neomorph is a biotechnology company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Repertoire Genesis
Repertoire Genesis is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
Investors List
DNV capital
DNV capital investment in Series B - Binhui Biotech
Hubei Provincial High Technology Industry Investment
Hubei Provincial High Technology Industry Investment investment in Series B - Binhui Biotech
Jointown Pharmaceutical Group
Jointown Pharmaceutical Group investment in Series B - Binhui Biotech
Yangtze River Pharmaceutical Group
Yangtze River Pharmaceutical Group investment in Series B - Binhui Biotech
Ming capital
Ming capital investment in Series B - Binhui Biotech
Yangtze River Pharmaceutical Group
Yangtze River Pharmaceutical Group investment in Venture Round - Binhui Biotech
Share Capital
Share Capital investment in Series C - Binhui Biotech
Vertex Ventures China
Vertex Ventures China investment in Series C - Binhui Biotech
Qianhai Fund of Funds
Qianhai Fund of Funds investment in Series C - Binhui Biotech
Lapam Capital
Lapam Capital investment in Series C - Binhui Biotech
Official Site Inspections
http://www.binhui-bio.com.cn
- Host name: 47.115.134.136
- IP address: 47.115.134.136
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Binhui Biotech"
Home - BINHUI BIOPHARM
Through the accumulation of technology, talents, and management experience gained over the last ten years in the R&D and industrialization of innovative anti-tumor drugs, Binhui Bio has developed a mature technical service platform for …See details»
首页 - 滨会生物
滨会生物科技有限公司研发及生产基地项目环境影响评价信息公示. 2024-10-14. 滨会生物oh2注射液临床数据在第27届全国临床肿瘤学大会暨2024年csco学术年会发布See details»
Company Profile - BINHUI BIOPHARM
Binhui Bio has four technology platforms: oncolytic virus (OV) immunotherapy platform (oHSV2), nucleic acid platform, protein platform and cell therapy platform. BS001 (OH2 injection), one of …See details»
公司简介 - 滨会生物 - binhui-bio.com.cn
武汉滨会生物科技股份有限公司于2010年注册成立，由已获批上市溶瘤病毒T-VEC（Imlygic）的原研团队主要成员刘滨磊博士创办，是一家专业从事生物新药研发、生产和技术服务的国家高新 …See details»
Binhui Biotech - Crunchbase Company Profile & Funding
Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent …See details»
Chinese Biotech Database
Binhui Bio has a cGMP pilot plant with multiple production lines that can be simultaneously used. With its high-content cell imaging system, bioreactor, in vivo imager, AKTA chromatography …See details»
Binhui Bio - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 6, 2025 Binhui Bio - Developer of oncolytic virus-based drugs. Raised a total funding of $158M over 4 rounds from 13 investors. Founded by Liu Binlei in the year 2010. Binhui Bio …See details»
Binhui Biopharmaceutical - Overview, News & Similar companies ...
Explore Complete Organization Structure. Is Binhui Biopharmaceutical your ideal customer? Let us give you the heads up on whether it's a good time to reach out. ... +86 2787326962 …See details»
Binhui Biopharma
CN. Shopping Cart (0) Home; Viral Vector. Viral Vector ... Shanghai Rainminda Pharmaceutical Technology Co., Ltd. is a wholly-owned subsidiary of Wuhan Binhui Biotechnology Co., Ltd., …See details»
主要投资人 - 滨会生物 - binhui-bio.com.cn
注册地址： 武汉东湖新技术开发区高新大道666号武汉国家生物产业基地项目b、c、d区研发楼b1栋2楼b272-4室See details»
Research Center - BINHUI BIOPHARM
BS001（CN） Melanoma. GBM. mCRC. Others. BS001(US) Melanoma with αPD-1 failure. BS001 combo with αPD-1 (CN) ... Info Disclosure e-mail：[email protected]. About Us. …See details»
Wuhan Binhui Biopharmaceutical Co., Ltd. - Drug pipelines
Mar 9, 2025 Explore Wuhan Binhui Biopharmaceutical Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 1 news, and 17 literature, Disease …See details»
写意会员 | 滨会生物：免疫治疗行业先锋_医药_新药_病毒
Mar 21, 2023 武汉滨会生物科技股份有限公司由获得美国FDA批准上市的溶瘤病毒药物T-VEC原研团队主要成员刘滨磊博士创办，是一家专业从事生物新药研发、生产和技术服务的高新技术 …See details»
咨询服务 - 滨会生物 - binhui-bio.com.cn
参照国内外法规要求建成溶瘤病毒、疫苗等中试生产车间. 2018-2021年先后获得中、美溶瘤病毒oh2单药、联合用药治疗晚期实体 ...See details»
Protein Products - BINHUI BIOPHARM
Binhui Bio has developed a clinically transformative protein technology platform capable of providing expression and purification services of micromolecular polypeptide and …See details»
Binhui Biopharm Nets Nearly USD 47 Million from Series B
Apr 21, 2022 Founded in 2010, Binhui Biopharm is a leading biotech dedicated to oncolytic virus immuno-oncology. Its drug candidate BS001 (OH2) injection is the world's first novel oncolytic …See details»
Cell Therapy - BINHUI BIOPHARM
Binhui Bio has a clinically transformative VAK (virus activated killer) cell therapy and Bat-T (BsAb activated) cell therapy platform and can provide the whole process design of preclinical and …See details»
研究中心 - 滨会生物 - binhui-bio.com.cn
候选药物. 适应症. 临床前研究. ind. 临床i期. 临床ii期. 临床iii期See details»
Cell Therapy Platform - BINHUI BIOPHARM
Binhui Bio's protein platform has the unique trimer domain (TD) antibody affinity purification technology for target protein that enables one-step purification of trimer protein. Since it is …See details»
FireflyLuciferase（Fluc）mRNA - 核酸产品 - 滨会生物
注册地址： 武汉东湖新技术开发区高新大道666号武汉国家生物产业基地项目b、c、d区研发楼b1栋2楼b272-4室See details»